SNAPduo 101
Virus-associated cancers
Pre-clinicalActive
Key Facts
About Black Canyon Bio
Black Canyon Bio is a private, pre-clinical stage biotech founded in 2021, headquartered in Denver, USA, and focused on the cancer vaccine sector. Its core asset is the SNAP platform, which aims to overcome key challenges in targeting patient-specific neoantigens to improve immunotherapy outcomes. The company's lead program, SNAPduo 101, a peptide vaccine for virus-associated cancers, is slated to enter clinical trials in 2026, positioning it in the competitive but high-potential field of personalized cancer vaccines.
View full company profileTherapeutic Areas
Other Virus-associated cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Equivir/Equivir G | Impact Biomedical | Preclinical |